Skip to content
Trending storyDeveloping

DCVax platform pairs patient dendritic cells with tumor antigens for blood cancers

1 article1 sourcesince Oct 11Last article 2h ago ·

Overview

AISummary of 1 article

Bosch argues that DCVax, which pairs a patient's tumor lysate with the patient's own dendritic cells, can serve as a platform for blood cancers including leukemias, lymphomas and myeloma.

The report does not describe a trial or clinical results for these cancers.

In human-cell experiments, Watchmaker and colleagues found that the type of dendritic cell shaped CD8 T cells' granzyme B expression, killing activity and tissue-homing receptors, not only how many of the T cells expanded.

Written by AI from the articles below · updated Oct 11, 4:26 PM ET

Check the sources:

Latest developmentOct 11, 3:11 PM ET
DCVax platform pairs patient dendritic cells with tumor antigens for blood cancers

Article timeline

The articles in this story. Times are ET.

Oct 11
  1. Andrew Caravello, DOX
    DCVax platform pairs patient dendritic cells with tumor antigens for blood cancers

    AIBosch argues that DCVax, which pairs a patient's tumor lysate with the patient's own dendritic cells, can serve as a platform for blood cancers including leukemias, lymphomas and myeloma. Watchmaker and colleagues showed in human-cell experiments that dendritic cell type shaped CD8 T cells' granzyme B expression, killing activity and tissue-homing receptors, not just their expansion.

Heat trend

Not enough continuous observations to show a trend yet.